TLR3 and prostate cancer: MD-1 is expressed in various cells, including macrophages, dendritic cells, B cells and monocytes.[34] MD-1 can interact with radioprotective 105 and mediates the response to lipopolysaccharide and regulation of the innate immune system and inflammation on the surface of immune cells, including B cells, macrophages, and dendritic cells.[35] LY86 was identified as a biomarker for the prediction of osteosarcoma, prostate cancer and renal cell carcinoma.[36–38] TLR3 encode toll-like receptor 3, which is a type of pathogen recognition receptor.